Drug Trial Radar · NCT01375920
Antiglucocorticoid Augmentation of antiDepressants in Depression
Last checked: Nov 20, 2026Latest source record: Jul 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
190
Actual
Start
Feb 2011
Primary completion
Feb 2013
Study completion Jun 2013
Sponsor
- Lead sponsor
- Jane BarnesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute for Health Research, United Kingdom
- First posted
- Jun 20, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Depression is one of the most common mental health problems, with at least one in six adults suffering from this at some time in their life. It can become long-lasting and frequently recurs. Depression has a large negative impact on quality of life of patients and their carers and it has also been shown to be one of the leading causes of working age adults receiving disability payments in the UK. The need for improved treatment has been recognised by the Department of Health and others. Improvements in drug treatments are therefore required. There has been recent increased understanding of some of the causes of the frequent lack of complete response seen with antidepressants. The stress hormone, cortisol, is often elevated or poorly controlled in depression and there is laboratory and clinical research to show that this hormonal change reduces the benefits from antidepressants with associated poor outcome and memory problems. Recently it has been shown in small studies that giving treatments that reduce cortisol or block its harmful effects for between 1 and 3 weeks overcome these negative consequences. Our group is particularly interested and experienced in this topic. The investigators plan to study a drug that decreases cortisol levels in people who have not recovered with standard antidepressants so that the investigators can find out the usefulness of this treatment (compared with placebo (dummy tablet)) in day to day life as well as checking closely for side-effects (the initial studies have shown that the particular drug the investigators wish to study (metyrapone) has few side effects). The investigators will also measure cortisol and see if its level can tell us which people do best with this treatment. The investigators will carry out this study in 3 centres across the UK. The investigators will carry out some additional tests of specific sorts of memory and decision making and also do this while scanning the brain (in a painless test). The results of these tests, along with tests of brain wave patterns, should help us understand more fully how this new treatment is working and who responds best to it. The study will help us find out if this drug should be used more widely for people not responding to standard treatments and will also lead on to the development of other new treatments with an anti-cortisol effect to help tackle the major problem of poor outcome from depression.
Conditions
- Depression
Interventions
MetyraponeDrug
500 milligrams to be taken twice a day orally
placeboDrug
a matched placebo will be administered to patients to take twice a day for 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary outcome will be the change in Montgomery-Asberg Depression Rating Scale (MADRS) from week 0 to +5 weeks.Time frame: 5 weeks
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Bradford District Care Trust
Bradford, United Kingdom
Leeds Community Mental Health Team
Leeds, United Kingdom
Affective Disorders Service
Manchester, United Kingdom
Manchester Community Mental Health Team
Manchester, United Kingdom
Manchester Magnetic Resonance Centre
Manchester, United Kingdom
Northumberland, Tyne and Wear NHS Foundation Trust
Newcastle upon Tyne, United Kingdom
Stockton Affective Disorders Service
Newcastle upon Tyne, Teesside, United Kingdom
Newcastle Community Mental Health Team
Newcastle upon Tyne, Tyne and Wear, United Kingdom
Regional Affective Disorders Service
Newcastle upon Tyne, Tyne and Wear, United Kingdom
North Tyneside Community Mental Health Team
Newcastle upon Tyne, Tyne and Wear, United Kingdom
Newcastle Magnetic Resonance Centre
Newcastle upon Tyne, Tyne and Wear, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.